Correction to: Advancement of antigen-specific immunotherapy: knowledge transfer between allergy and autoimmunity [0.03%]
特刊：过敏和自身免疫之间知识转移推动特异性免疫疗法进步的评论
[This corrects the article DOI: 10.1093/immadv/ltab009.]. © The Author(s) 2023. Published by Oxford University Press on behalf of the British Society fo...
Published Erratum
Immunotherapy advances. 2023 Jul 27;3(1):ltad004. DOI:10.1093/immadv/ltad004 2023
Blockade of innate inflammatory cytokines TNF α, IL-1 β, or IL-6 overcomes virotherapy-induced cancer equilibrium to promote tumor regression [0.03%]
阻断天然炎症因子TNFα、IL-1β或IL-6可克服病毒疗法引起的肿瘤平衡以促进肿瘤消退
Michael J Walsh,Lestat R Ali,Patrick Lenehan et al.
Michael J Walsh et al.
Cancer therapeutics can lead to immune equilibrium in which the immune response controls tumor cell expansion without fully eliminating the cancer. The factors involved in this equilibrium remain incompletely understood, especially those th...
Leveraging the lymphohematopoietic graft-versus-host reaction (LGVHR) to achieve allograft tolerance and restore self tolerance with minimal toxicity [0.03%]
利用淋巴血细胞移植物抗宿主反应(LGVHR)实现同种异体移植耐受并最小限度毒性地恢复自身耐受性
Megan Sykes
Megan Sykes
Mixed allogeneic chimerism has considerable potential to advance the achievement of immune tolerance to alloantigens for transplantation and the restoration of self-tolerance in patients with autoimmune disease. In this article, I review ev...
Treg-based immunotherapy for antigen-specific immune suppression and stable tolerance induction: a perspective [0.03%]
基于Treg的免疫治疗在抗原特异性免疫抑制和耐受诱导中的作用：展望
Shimon Sakaguchi,Ryoji Kawakami,Norihisa Mikami
Shimon Sakaguchi
FoxP3-expressing regulatory T cells (Tregs), whether naturally generated in the immune system or unnaturally induced from conventional T cells (Tconvs) in the laboratory, have much therapeutic value in treating immunological diseases and es...
Akshay J Patel,Gary W Middleton
Akshay J Patel
In this review, we explore the biology of the TIGIT checkpoint and its potential as a therapeutic target in lung cancer. We briefly review a highly selected set of clinical trials that have reported or are currently recruiting in non-small ...
Martin Fellermeyer,Consuelo Anzilotti,Christopher Paluch et al.
Martin Fellermeyer et al.
There is an increasing number of immune-checkpoint inhibitors being developed and approved for cancer immunotherapy. Most of the new therapies aim to reactivate tumour-infiltrating T cells, which are responsible for tumour killing. However,...
A systems approach evaluating the impact of SARS-CoV-2 variant of concern mutations on CD8+ T cell responses [0.03%]
系统评估SARS-CoV-2变异株的关切突变对CD8+t细胞反应的影响
Paul R Buckley,Chloe H Lee,Agne Antanaviciute et al.
Paul R Buckley et al.
T cell recognition of SARS-CoV-2 antigens after vaccination and/or natural infection has played a central role in resolving SARS-CoV-2 infections and generating adaptive immune memory. However, the clinical impact of SARS-CoV-2-specific T c...
Correction to: Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor [0.03%]
Correction to: TIM-3受体靶向的新型免疫疗法savapritumab(SAB007)的作用机制及活性特征
[This corrects the article DOI: 10.1093/immadv/ltac019.]. © The Author(s) 2023. Published by Oxford University Press on behalf of the British Society fo...
Published Erratum
Immunotherapy advances. 2023 Feb 18;3(1):ltad002. DOI:10.1093/immadv/ltad002 2023
Correction to: Peripheral blood persistence and expansion of transferred non-genetically modified Natural Killer cells might not be necessary for clinical activity [0.03%]
Correction to: 嵌合抗原受体修饰的自然杀伤细胞治疗实体瘤的安全性研究：I 期临床试验结果
[This corrects the article DOI: 10.1093/immadv/ltac024.]. © The Author(s) 2023. Published by Oxford University Press on behalf of the British Society fo...
Published Erratum
Immunotherapy advances. 2023 Feb 18;3(1):ltad003. DOI:10.1093/immadv/ltad003 2023
Stratification of PD-1 blockade response in melanoma using pre- and post-treatment immunophenotyping of peripheral blood [0.03%]
基于外周血免疫分型的黑色素瘤PD-1阻断反应分类研究
Natalie M Edner,Elisavet Ntavli,Lina Petersone et al.
Natalie M Edner et al.
Efficacy of checkpoint inhibitor therapies in cancer varies greatly, with some patients showing complete responses while others do not respond and experience progressive disease. We aimed to identify correlates of response and progression f...